US 12,303,561 B2
Protein antigens and uses thereof
Michael Steven Rooney, Boston, MA (US)
Assigned to BioNTech US Inc., Cambridge, MA (US)
Appl. No. 16/500,707
Filed by BioNTech US Inc., Cambridge, MA (US)
PCT Filed Apr. 3, 2018, PCT No. PCT/US2018/025933
§ 371(c)(1), (2) Date Oct. 3, 2019,
PCT Pub. No. WO2018/187356, PCT Pub. Date Oct. 11, 2018.
Claims priority of provisional application 62/480,593, filed on Apr. 3, 2017.
Claims priority of provisional application 62/480,596, filed on Apr. 3, 2017.
Claims priority of provisional application 62/480,597, filed on Apr. 3, 2017.
Prior Publication US 2023/0241207 A1, Aug. 3, 2023
Int. Cl. A61K 39/245 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC A61K 39/245 (2013.01) [A61K 39/0011 (2013.01); A61K 39/4615 (2023.05); A61K 39/4622 (2023.05); A61K 39/4644 (2023.05); A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 24 Claims
 
1. A method of treating a cancer in a subject in need thereof, the method comprising administering to the subject a polypeptide or a polynucleotide encoding the polypeptide, wherein the polypeptide comprises an amino acid sequence comprising at least 8 contiguous amino acids of a viral protein epitope sequence encoded by (I) an E6 gene of Human papillomavirus type 16 (HPV-16) or (II) an E7 gene of HPV-16, wherein:
(a) the subject expresses an MHC encoded by an HLA B07:02 allele and wherein the amino acid sequence is encoded by the E6 gene of HPV-16 and comprises a sequence of RGRWTGRCM (SEQ ID NO: 70);
(b) the subject expresses an MHC encoded by an HLA B08:01 allele and wherein the amino acid sequence is encoded by the E6 gene of HPV-16; or
(c) the subject expresses an MHC encoded by an HLA A24:02 allele and
(i) the amino acid sequence is encoded by the E7 gene of HPV-16 and comprises the sequence of RAHYNIVTF (SEQ ID NO: 83), or
(ii) the amino acid sequence is encoded by the E6 gene of HPV-16 and comprises a sequence of MHQKRTAMF (SEQ ID NO: 66);
wherein the cancer is a cancer expressing an antigen encoded by the E6 gene of HPV-16 or the E7 gene of HPV-16; and wherein the subject is a human.